Squarepoint Ops LLC Adagio Therapeutics, Inc. Transaction History

Squarepoint Ops LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	N/A	-209,896 Reduced 73.79%	74,565 $246,000
Q1 2024 May 15, 2024	BUY	N/A	182,071 Added 177.82%	284,461 $941,000
Q4 2023 Feb 14, 2024	SELL	N/A	-116,337 Reduced 53.19%	102,390 $338,000
Q2 2023 Aug 14, 2023	BUY	N/A	203,890 Added 1374.2%	218,727 $723,000
Q1 2023 May 15, 2023	SELL	N/A	-35,703 Reduced 70.64%	14,837 $49,000
Q4 2022 Feb 14, 2023	BUY	$3.08 - $4.05 $155,663 - $204,687	50,540 New	50,540 $167,000
Q2 2022 Aug 15, 2022	SELL	$2.54 - $4.52 $13,774 - $24,511	-5,423 Reduced 33.43%	10,800 $35,000
Q1 2022 May 16, 2022	SELL	$3.81 - $10.77 $1,322 - $3,737	-347 Reduced 2.09%	16,223 $74,000
Q4 2021 Feb 14, 2022	BUY	$6.35 - $47.04 $105,219 - $779,452	16,570 New	16,570 $120,000

63.9M

2.3K

2.1K

Ticker ADGI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,831,000
Market Cap $505M
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.